Table 1. Non–gene-modified T-cell... | American Society of Hematology

Table 1.

Non–gene-modified T-cell therapies available for patients with lymphoma

Treatment approach	Description
Unmodified DLI^35-44	Infusion of donor lymphocytes to mount GVT response
Modified DLI^45-49,71	Depletion of DLI subpopulations, T_REG, naive T cells, to select for most potent CTLs
Tumor antigen–targeted CTLs^50-55,88	Infusion of ex vivo expanded tumor-specific allogeneic or autologous CTLs for elimination of tumor targets
Viral antigen–targeted T cells^56,72,84	Infusion of ex vivo–expanded virus-specific allogeneic or autologous T-cells to minimize viral reactivation during the immunosuppressive period posttransplant
Tumor peptide–loaded DC vaccination^57-60	Infusion of peptide-loaded DCs for in vivo presentation of antigen to endogenous T cells

Treatment approach	Description
Unmodified DLI^35-44	Infusion of donor lymphocytes to mount GVT response
Modified DLI^45-49,71	Depletion of DLI subpopulations, T_REG, naive T cells, to select for most potent CTLs
Tumor antigen–targeted CTLs^50-55,88	Infusion of ex vivo expanded tumor-specific allogeneic or autologous CTLs for elimination of tumor targets
Viral antigen–targeted T cells^56,72,84	Infusion of ex vivo–expanded virus-specific allogeneic or autologous T-cells to minimize viral reactivation during the immunosuppressive period posttransplant
Tumor peptide–loaded DC vaccination^57-60	Infusion of peptide-loaded DCs for in vivo presentation of antigen to endogenous T cells

DLI, donor lymphocyte infusion; T_REG, regulatory T cell.